



# Proteomics International

LABORATORIES LTD

ASX Release  
16 November 2021

ASX code: PIQ

## Director appointments

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) today announced the appointments of Robyn Elliott and Neville Gardiner to its Board as independent, non-executive Directors, effective 16 November 2021.

Mr Gardiner was recently a Partner of Deloitte in its M&A Advisory team. He is a seasoned finance professional with over 30 years' experience advising Boards of public and private companies on mergers and acquisitions, project development, equity and debt capital markets, transaction structuring, capital allocation and complex commercial problem solving. Prior to Deloitte Mr Gardiner was Co-Founder and Managing Director of Torridon Partners, an independent corporate advisory firm. Torridon Partners was acquired by Deloitte in 2016.

Mr Gardiner holds a Bachelor of Business (Accounting and Business Law) from Curtin University, and is a Member of Chartered Accountants Australia and the Australian Institute of Company Directors. He has held leadership positions at Macquarie Bank, Bank of America Merrill Lynch and Arthur Anderson, and has broad industry sector exposure including health-tech, fin-tech, mining and mining services, infrastructure, energy, and fabrication and construction. Mr Gardiner will assume the role of Chair-elect.

Dr Elliott is Executive Director, Strategic Fractionation Program Delivery within the Global Network Strategy team CSL Behring, a subsidiary of CSL Limited (ASX:CSL). Her role is responsible for business value delivery from a billion dollar global capital expansion portfolio. She is also non-executive Director of PolyNovo Limited (ASX:PNV)

Dr Elliott's 9 years at CSL Behring have included Senior Director roles for Strategic Expansion Projects and Quality, including supporting the global network strategy team determining the ten-year expansion plan for the CSL Behring global business. Dr Elliott holds a Doctor of Philosophy and a Bachelor of Science (Honours) from Monash University. Prior to CSL Behring she was Managing Director at IDT Australia Ltd (ASX:IDT) and commenced her career at DBL Faulding.

Dr Elliott has a proven track record in product development, clinical trials, regulatory affairs, audits, quality management, project management and operational strategy. Her worldwide experience in new facility delivery, production scale up, strategic planning and governance will be of significant benefit to Proteomics International as it drives expansion of its commercial operations.

Proteomics International Managing Director Dr Richard Lipscombe said he was delighted to welcome Dr Elliott and Mr Gardiner to the Board.

*"Robyn and Neville bring a fantastic combination of skills to further strengthen our team. At this pivotal stage in our company's development their wealth of knowledge will be invaluable. With operational insights from Australia's most successful life science company and tier one capital markets experience we look forward to them accelerating the next phase of Proteomics International's growth."*

Mr Gardiner and Dr Elliott said that they were excited to join the PIQ Board at a time when the company was poised for substantial growth, and with enormous opportunities across its deepening pipeline of innovative tools for the improved treatment of disease.

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Authorised by the Board of Proteomics International Laboratories Ltd (ASX:PIQ).

ENDS

**About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

**For further information please contact:**

Dr Richard Lipscombe

Managing Director

Proteomics International Laboratories Ltd

T: +61 8 9389 1992

E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel

Investor Relations & Corporate Advisor

Candour Advisory

T: +61 408 326 367

E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

Kyle Moss

Corporate Advisor

Euroz Hartleys

T: +61 8 9488 1400

E: [kmoss@eurozhartleys.com](mailto:kmoss@eurozhartleys.com)